Table 2.

Predictive molecular tests: selected examples.

Drugs	Markers	References
Tamoxifen and aromatase inhibitors	Estrogen receptor expression	Fujii et al., 2017
HER2-directed therapies	HER2 amplification and overexpression	Sartore-Bianchi et al., 2016
ALK/ROS1 inhibitors	ALK and ROS1 rearrangements	Soda et al., 2007; Kwak et al., 2009; Shaw et al., 2014
EGFR-directed therapies (sensitivity)	EGFR mutations	Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004
EGFR-directed therapies (resistance)	KRAS/NRAS/BRAF mutations	Siddiqui and Piperdi, 2010; Waring et al., 2016; van Brummelen et al., 2017
PARP inhibitors	BRCA1/2 mutations, BRCAness	Iyevleva and Imyanitov, 2016; Lord and Ashworth, 2016
Platinum compounds, mitomycin C	BRCA1/2 mutations, BRCAness	Iyevleva and Imyanitov, 2016; Lord and Ashworth, 2016
PD1-directed therapies	High PD-L1 expression	Kumar et al., 2017
Immune checkpoint inhibitors	Tumor mutation burden	Rizvi et al., 2015
BRAF inhibitors	BRAF mutations	Ugurel et al., 2017; Cheng et al., 2018
mTOR inhibitors	TSC1/2 mutations, MTOR mutations	Kwiatkowski et al., 2016
MET inhibitors	MET exon 14 skipping	Pilotto et al., 2017